
Ministry of Food and Drug Safety (MFDS)
Korea’s regulator for food and medicines, including advanced biopharmaceuticals such as cell therapy products.
The Ministry of Food and Drug Safety regulates medicines in Korea. Under the Advanced Regenerative Bio Act, it oversees advanced biopharmaceuticals such as cell therapy products, including licences to manufacture them and long-term follow-up of certain products. It runs the treatment plan review committee jointly with the Ministry of Health and Welfare, and its approval is needed for the highest-risk clinical research.
This is different from the Ministry of Health and Welfare, which designates the institutions that may carry out advanced regenerative medicine.
Practical check: when a clinic says something is “approved”, ask whether it means a medicine approved by the MFDS or a treatment plan approved by the review committee. They are different approvals.
Related terms
- Cell therapy product
- A medicine made from living cells that have been cultured, multiplied, selected or otherwise processed outside the body.
- Treatment plan review committee
- The Korean government committee that reviews each advanced regenerative medicine research plan and treatment plan before a designated institution may use it.
- Clinical research
- Research on people that tests an advanced regenerative therapy under a reviewed plan, separate from routine treatment.
Not sure where to start?
Send your question and any X-ray or MRI report you have. COMEDI, the registered coordinator that runs this guide, replies in writing and can ask a clinic for its written answer and an itemised quote.